ARGX vs. DHR: argenx vs. Danaher Stock Comparison
How do argenx (ARGX) and Danaher (DHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
argenx (ARGX) and Danaher (DHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while DHR is classified in Life Sciences Tools & Services.
Danaher (DHR) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ARGX | DHR |
|---|---|---|
| Name | argenx SE American Depositary Receipt | Danaher Corp. |
| Country/Region | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 58.31 billion USD | 161.86 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | May 18, 2017 | December 29, 1978 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ARGX | DHR |
|---|---|---|
| Total Return (1Y) | 11.91% | 11.88% |
| Total Return (3Y, Annualized) | 25.68% | 6.67% |
| Total Return (5Y, Annualized) | 24.22% | -2.05% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ARGX | DHR |
|---|---|---|
| Volatility (1Y, Annualized) | 37.87% | 30.61% |
| Beta (5Y) | 0.45 | 0.76 |
| Max Drawdown (5Y) | -38.20% | -43.31% |
| Avg. Volume (3M) | 359.84K | 3.94M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ARGX | DHR |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 0.25 |
| Sortino Ratio (1Y) | 0.31 | 0.35 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Danaher (DHR) earns 8.19% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 109.18%
- DHR
- 8.19%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
argenx (ARGX) at 31.73% keeps the most of each sales dollar — above its industry’s net margin range — and Danaher (DHR) at 16.91% also retains a top-quartile share.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.91%
- Max
- 18.05%
- DHR
- 16.91%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both argenx (ARGX) at 36.27% and Danaher (DHR) at 21.13% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.13%
- Max
- 83.12%
- DHR
- 21.13%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ARGX | DHR |
|---|---|---|
| ROE (TTM) | -- | 8.19% |
| ROA (TTM) | -- | 4.06% |
| Net Margin (TTM) | 31.73% | 16.91% |
| Operating Margin (TTM) | 36.27% | 21.13% |
| Gross Margin (TTM) | 59.84% | 59.36% |
Growth
Revenue Growth
argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Danaher (DHR) at 2.90% is closer to the peer norm — faster top-line expansion for ARGX.
EPS Growth
Both argenx (ARGX) at 53.13% and Danaher (DHR) at -4.54% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | ARGX | DHR |
|---|---|---|
| Revenue Growth (YoY) | 89.64% | 2.90% |
| Revenue Growth (3Y CAGR) | 116.25% | -2.67% |
| EPS Growth (YoY) | 53.13% | -4.54% |
| EPS Growth (3Y CAGR) | -- | -19.44% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Danaher (DHR) shows current ratio of 1.63 against its industry benchmark, while argenx (ARGX) has no reading this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- DHR
- 1.63
- Min
- 0.10
Debt / Equity (MRQ)
argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Danaher (DHR) at 0.52 runs a more typical debt-to-equity mix.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.52
- Max
- 1.42
- Q3
- 0.65
- DHR
- 0.52
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ARGX | DHR |
|---|---|---|
| Current Ratio (MRQ) | -- | 1.63 |
| Debt / Equity (MRQ) | 0.01 | 0.52 |
| Net Debt / EBITDA | -2.70 | 2.68 |
Dividends
Dividend Yield (TTM)
argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67%
- DHR
- 0.67%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
argenx (ARGX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.17%
- DHR
- 25.17%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ARGX | DHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.67% |
| Dividend Payout Ratio (TTM) | 0.00% | 25.17% |
Valuation
P/E Ratio (TTM)
Both argenx (ARGX) at 32.12 and Danaher (DHR) at 38.12 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.12
- Max
- 85.34
- Q3
- 43.46
- DHR
- 38.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both argenx (ARGX) at 9.86 and Danaher (DHR) at 6.32 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.32
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- DHR
- 6.32
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Danaher (DHR) at 3.02 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.02
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- DHR
- 3.02
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ARGX | DHR |
|---|---|---|
| P/E Ratio (TTM) | 32.12 | 38.12 |
| P/S Ratio (TTM) | 9.86 | 6.32 |
| P/B Ratio (MRQ) | 172.23 | 3.02 |
| Free Cash Flow Yield (TTM) | -- | 2.93% |